ZA93779B - Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. - Google Patents

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Info

Publication number
ZA93779B
ZA93779B ZA93779A ZA93779A ZA93779B ZA 93779 B ZA93779 B ZA 93779B ZA 93779 A ZA93779 A ZA 93779A ZA 93779 A ZA93779 A ZA 93779A ZA 93779 B ZA93779 B ZA 93779B
Authority
ZA
South Africa
Prior art keywords
cloning
expression
design
monoclonal antibodies
antibodies against
Prior art date
Application number
ZA93779A
Other languages
English (en)
Inventor
Chuan-Chu Chou
John S Abrams
Mary E Petro
Stephen Tindall
Paul J Zavodny
Nicholas J Murgolo
Chung-Her Jenh
Jon E Silver
William T Windsor
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA93779B publication Critical patent/ZA93779B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA93779A 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. ZA93779B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
ZA93779B true ZA93779B (en) 1993-08-05

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA93779A ZA93779B (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Country Status (21)

Country Link
US (1) US6451982B1 (2)
EP (1) EP0625201A1 (2)
JP (2) JPH07505767A (2)
KR (2) KR0150060B1 (2)
CN (1) CN1077991A (2)
AR (1) AR248044A1 (2)
AU (1) AU683836B2 (2)
CA (1) CA2129445A1 (2)
CZ (1) CZ291039B6 (2)
FI (1) FI943635L (2)
HU (1) HUT67943A (2)
IL (1) IL104620A (2)
NO (1) NO942912L (2)
NZ (1) NZ249633A (2)
PL (1) PL176393B1 (2)
RU (1) RU94045919A (2)
SG (1) SG49597A1 (2)
SK (1) SK280610B6 (2)
TN (1) TNSN93012A1 (2)
WO (1) WO1993016184A1 (2)
ZA (1) ZA93779B (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
WO1996021000A2 (en) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素-5受体α链的抗体
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2868618C (en) * 2002-10-16 2017-05-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2585977C (en) 2004-10-28 2013-07-02 Kyowa Hakko Kogyo Co., Ltd. Remedy for endometriosis
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗il−5抗体を投与するための方法
WO2009120927A2 (en) 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
US20110229903A1 (en) * 2008-10-23 2011-09-22 Ulrich Goepfert Determination of immunoglobulin encoding nucleic acid
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CA3064859A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌcd20モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
CN111065651B (zh) * 2017-09-29 2023-07-14 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业(上海)股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ZA898322B (en) * 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
AU683836B2 (en) 1997-11-27
FI943635A7 (fi) 1994-08-05
KR0150060B1 (ko) 1998-08-17
FI943635A0 (fi) 1994-08-05
IL104620A0 (en) 1993-06-10
CZ191094A3 (en) 1994-12-15
NO942912L (no) 1994-10-06
CN1077991A (zh) 1993-11-03
JPH07505767A (ja) 1995-06-29
HU9402293D0 (en) 1994-10-28
SG49597A1 (en) 1998-06-15
JP2000210097A (ja) 2000-08-02
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
RU94045919A (ru) 1996-11-10
FI943635L (fi) 1994-08-05
AR248044A1 (es) 1995-05-31
SK91894A3 (en) 1995-02-08
KR950700413A (ko) 1995-01-16
CZ291039B6 (cs) 2002-12-11
NO942912D0 (2) 1994-08-05
HUT67943A (en) 1995-05-29
US6451982B1 (en) 2002-09-17
TNSN93012A1 (fr) 1994-03-17
IL104620A (en) 2000-02-29
EP0625201A1 (en) 1994-11-23
SK280610B6 (sk) 2000-05-16
CA2129445A1 (en) 1993-08-07
AU3656093A (en) 1993-09-03
NZ249633A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ZA93779B (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
ZA949341B (en) Humanized antibodies and uses thereof
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
EP0578515A3 (en) Humanized monoclonal antibodies.
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
EP0198086A4 (en) MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
ZA9510195B (en) Monoclonal antibody fragments having immunosuppressant activity
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
HK1008833A (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
PL323195A1 (en) Alpha unit of human integrin beta 2
AU6777594A (en) Human monoclonal antibodies to human cytomegalovirus, and methods therefor
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
HK1010986A (en) Humanized chimeric anti-icam-1 antibodies, methods of preparation and use
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
GB9118013D0 (en) Monoclonal antibodies and their use
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use
GB9210929D0 (en) Monoclonal antibodies and their use